破局肺癌长生存难题 百泽安全线刷新OS获益纪录

E药经理人
Sep 30

在中国发病率、死亡率居首的肺癌领域,患者追求长期生存的目标,正变得不再遥不可及。9月,一年一度的世界肺癌大会(WCLC)如期召开,在持续关注肺癌这一“头号癌种”的同时,进一步将焦点锁定在总生存期(OS)获益这一抗癌疗效“金标准”上。要知道,中国是肺癌大国,根据国家癌症中心2025年发布的全国癌症报告,2022年中国肺癌新发人数为106.06万,死亡人数为73.33万,均位居癌症首位,成为威胁国民...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10